China will continue investigations of wrongdoing by drug companies

07/24/2013 | West Australian, The

Investigations of bribery and corruption involving international pharmaceutical companies may expand in the near future, according to China's Xinhua news agency, which is said to reflect government thinking. Along with previous charges brought against GlaxoSmithKline, Chinese authorities have questioned employees of AstraZeneca and Belgian drugmaker UCB. Around 1,000 doctors, nurses and administrators at 73 hospitals in Zhangzhou have reportedly taken kickbacks.

View Full Article in:

West Australian, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations